IL311675A - Anti-complement factor BB antibodies and their uses - Google Patents
Anti-complement factor BB antibodies and their usesInfo
- Publication number
- IL311675A IL311675A IL311675A IL31167524A IL311675A IL 311675 A IL311675 A IL 311675A IL 311675 A IL311675 A IL 311675A IL 31167524 A IL31167524 A IL 31167524A IL 311675 A IL311675 A IL 311675A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- seq
- amino acid
- present disclosure
- cases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317897P | 2016-04-04 | 2016-04-04 | |
| PCT/US2017/025784 WO2017176651A1 (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor bb antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311675A true IL311675A (en) | 2024-05-01 |
Family
ID=60000646
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311675A IL311675A (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor BB antibodies and their uses |
| IL295288A IL295288B2 (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor BB antibodies and their uses |
| IL262010A IL262010B (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor bb antibodies and their uses |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295288A IL295288B2 (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor BB antibodies and their uses |
| IL262010A IL262010B (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor bb antibodies and their uses |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10934347B2 (https=) |
| EP (1) | EP3452510A4 (https=) |
| JP (4) | JP6967528B2 (https=) |
| KR (2) | KR20240096672A (https=) |
| CN (2) | CN116790614A (https=) |
| AU (2) | AU2017246794B2 (https=) |
| BR (1) | BR112018070357A2 (https=) |
| CA (1) | CA3019332A1 (https=) |
| CL (1) | CL2018002810A1 (https=) |
| CO (1) | CO2018010827A2 (https=) |
| CR (1) | CR20180529A (https=) |
| DO (1) | DOP2018000219A (https=) |
| EA (1) | EA201892225A1 (https=) |
| EC (1) | ECSP18082302A (https=) |
| IL (3) | IL311675A (https=) |
| MA (1) | MA44878A (https=) |
| MX (2) | MX2018012176A (https=) |
| MY (1) | MY194603A (https=) |
| PE (1) | PE20190209A1 (https=) |
| PH (1) | PH12018502137A1 (https=) |
| SG (1) | SG11201808525UA (https=) |
| TN (1) | TN2018000341A1 (https=) |
| WO (1) | WO2017176651A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI542597B (zh) | 2010-07-28 | 2016-07-21 | 吉林尼克公司 | 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白 |
| KR20250053203A (ko) | 2015-07-24 | 2025-04-21 | 글리크닉 인코포레이티드 | 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질 |
| EP3452510A4 (en) | 2016-04-04 | 2020-01-15 | Bioverativ USA Inc. | ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF |
| CN110022898B (zh) | 2016-12-09 | 2023-07-04 | 格利克尼克股份有限公司 | 用多价Fc化合物治疗炎性疾病的方法 |
| MX2019006573A (es) | 2016-12-09 | 2019-11-18 | Gliknik Inc | Optimizacion de fabricacion de gl-2045 un stradomer multimerizante. |
| US11690919B2 (en) * | 2017-01-17 | 2023-07-04 | The Texas A&M University System | Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells |
| JP7369121B2 (ja) * | 2017-10-11 | 2023-10-25 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 補体活性を誘発する方法 |
| EP3728568A4 (en) | 2017-12-19 | 2021-10-06 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS FOR DELIVERING VIRAL VECTORS BY THE BLOOD-BRAIN BARRIER |
| KR20220042128A (ko) * | 2019-06-27 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도 |
| TWI851771B (zh) * | 2019-07-17 | 2024-08-11 | 美商雙子治療子公司 | 因子ｈ增強抗體及其用途 |
| US20230050339A1 (en) * | 2020-02-18 | 2023-02-16 | Children's Hospital Medical Center | Compositions and methods for treating liver disease |
| EP4139350A4 (en) | 2020-04-20 | 2024-04-24 | Genzyme Corporation | Humanized anti-complement factor bb antibodies and uses thereof |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| KR100551104B1 (ko) | 1994-12-09 | 2006-02-09 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의 동정 |
| WO1996019487A1 (en) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Organobismuth derivatives and process for producing the same |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| ES2166097T5 (es) | 1996-08-27 | 2007-03-16 | Novartis Vaccines And Diagnostics, Inc. | Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| KR20010015856A (ko) | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| PL1713503T3 (pl) | 2004-02-10 | 2014-02-28 | Univ Colorado Regents | Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby |
| US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| SG10201804008UA (en) | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| NZ616992A (en) * | 2005-12-20 | 2015-07-31 | Sbi Biotech Co Ltd | Anti-ilt7 antibody |
| WO2007071061A1 (en) * | 2005-12-23 | 2007-06-28 | Viventia Biotech Inc. | Methods for generating and screening fusion protein libraries and uses thereof |
| CN101970002B (zh) * | 2007-08-27 | 2016-05-18 | 诺福麦德治疗学股份有限公司 | 用因子Bb特异性抗体抑制补体活化的方法 |
| US8158762B2 (en) * | 2007-11-08 | 2012-04-17 | Genentech, Inc. | Anti-factor B antibodies and their uses |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| US8784819B2 (en) * | 2009-09-29 | 2014-07-22 | Ibio Inc. | Influenza hemagglutinin antibodies, compositions and related methods |
| JP2015502340A (ja) | 2011-10-27 | 2015-01-22 | エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｉＮＫＴに対するヒト化抗体 |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| US9243070B2 (en) * | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor Bb antibodies and uses thereof |
| WO2014044793A2 (en) | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| ES2731681T3 (es) | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| US9260527B2 (en) * | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| WO2015051159A1 (en) * | 2013-10-02 | 2015-04-09 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| CN110724691A (zh) * | 2014-02-27 | 2020-01-24 | 阿勒根公司 | 补体因子Bb抗体 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| EP3452510A4 (en) | 2016-04-04 | 2020-01-15 | Bioverativ USA Inc. | ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF |
| JP7369121B2 (ja) | 2017-10-11 | 2023-10-25 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 補体活性を誘発する方法 |
| EP4139350A4 (en) | 2020-04-20 | 2024-04-24 | Genzyme Corporation | Humanized anti-complement factor bb antibodies and uses thereof |
-
2017
- 2017-04-03 EP EP17779607.5A patent/EP3452510A4/en active Pending
- 2017-04-03 IL IL311675A patent/IL311675A/en unknown
- 2017-04-03 PE PE2018001946A patent/PE20190209A1/es unknown
- 2017-04-03 JP JP2018552076A patent/JP6967528B2/ja active Active
- 2017-04-03 BR BR112018070357-5A patent/BR112018070357A2/pt active Search and Examination
- 2017-04-03 CA CA3019332A patent/CA3019332A1/en active Pending
- 2017-04-03 WO PCT/US2017/025784 patent/WO2017176651A1/en not_active Ceased
- 2017-04-03 AU AU2017246794A patent/AU2017246794B2/en active Active
- 2017-04-03 CN CN202210862505.3A patent/CN116790614A/zh active Pending
- 2017-04-03 IL IL295288A patent/IL295288B2/en unknown
- 2017-04-03 CR CR20180529A patent/CR20180529A/es unknown
- 2017-04-03 MA MA044878A patent/MA44878A/fr unknown
- 2017-04-03 TN TNP/2018/000341A patent/TN2018000341A1/en unknown
- 2017-04-03 KR KR1020247018546A patent/KR20240096672A/ko active Pending
- 2017-04-03 IL IL262010A patent/IL262010B/en unknown
- 2017-04-03 US US16/091,447 patent/US10934347B2/en active Active
- 2017-04-03 KR KR1020187031483A patent/KR102673420B1/ko active Active
- 2017-04-03 CN CN201780029742.9A patent/CN109563158B/zh active Active
- 2017-04-03 MX MX2018012176A patent/MX2018012176A/es unknown
- 2017-04-03 EA EA201892225A patent/EA201892225A1/ru unknown
- 2017-04-03 MY MYPI2018001682A patent/MY194603A/en unknown
- 2017-04-03 SG SG11201808525UA patent/SG11201808525UA/en unknown
-
2018
- 2018-10-03 CL CL2018002810A patent/CL2018002810A1/es unknown
- 2018-10-04 PH PH12018502137A patent/PH12018502137A1/en unknown
- 2018-10-04 DO DO2018000219A patent/DOP2018000219A/es unknown
- 2018-10-04 MX MX2023007149A patent/MX2023007149A/es unknown
- 2018-10-09 CO CONC2018/0010827A patent/CO2018010827A2/es unknown
- 2018-10-31 EC ECSENADI201882302A patent/ECSP18082302A/es unknown
-
2021
- 2021-01-19 US US17/151,860 patent/US11851482B2/en active Active
- 2021-09-10 JP JP2021147485A patent/JP7326393B2/ja active Active
-
2023
- 2023-08-02 JP JP2023126155A patent/JP2023139289A/ja active Pending
- 2023-11-08 US US18/504,416 patent/US20240228599A1/en active Pending
-
2024
- 2024-09-30 AU AU2024224000A patent/AU2024224000A1/en active Pending
-
2025
- 2025-11-14 JP JP2025194917A patent/JP2026069789A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11851482B2 (en) | Anti-complement factor Bb antibodies and uses thereof | |
| US20220204647A1 (en) | Anti-complement c1s antibodies and uses thereof | |
| CA3142634A1 (en) | Anti-b7-h3 antibody and methods of use thereof | |
| NZ786930A (en) | Anti-complement factor Bb antibodies and uses thereof | |
| HK40063408A (en) | Anti-complement c1s antibodies and uses thereof | |
| HK40006720A (en) | Anti-complement factor bb antibodies and uses thereof |